SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Quartet

Quadripolar LV Lead

Clinical Evidence

Clinical Evidence

Quadripolar Advantages for Cardiac Resynchronization Therapy

Cardiac resynchronization therapy (CRT) is an effective treatment for heart failure, and it can help your patients avoid life-threatening changes in heart rhythm. CRT can also alleviate many of the symptoms experienced by your patients, improving their overall quality of life.

Quadripolar technology offers a significant advantage over bipolar technology—giving you the flexibility you need to access pacing sites and vectors outside of the reach of most devices, without compromising lead stability or performance.
 

Our Quadripolar CRT System is Associated with Increased Survival

Patients with a quadripolar system may receive more effective CRT than those with bipolar LV pacing:4

Mortality results

Mortality incidence was significantly lower in the quadripolar group.10

  • Quadripolar: 5.04 deaths per 100 patient-years
  • Bipolar: 6.45 deaths per 100 patient-years (p = 0.001)

After multivariate adjustment, the quadripolar lead was associated with a lower risk of death HR: 0.77; 95% CI: 0.69 to 0.86; p < 0.001.10

Mortality conclusions

CRT with quadripolar LV system was associated with a 22% relative reduction in mortality compared with a bipolar LV system.10

Operational efficiency, implant success and lead performance

In clinical studies, quadripolar pacing technology has resulted in:

  • Significantly lower risk of lead deactivation or replacement than bipolar leads3
Lower rates of deactiviation and replacement twelve months post-implant for the Quartet LV lead compared to Bipolar technology.

Benefits of Quadripolar Technology

The use of quadripolar technology offers you and your hospital or clinic many clinical, economic and operational advantages over bipolar technology, including:

Reduced cost

39.8% reduction in

Heart Failure hospitalization cost6

97.4% of patients

Successfully implanted after 18 months Once placed, the LV lead remained stable with excellent pacing threshoolds during follow-up (15 ± 5 months)1

54% lower

hospitalization rate5

Overall cost savings

(effective resource utilization)7

Extended battery life by up to 17 months

Among patients with high capture thresholds the use of a quadripolar lead extended battery life significantly4

32.1% reduction

of 30-day readmission rate6

Reduction in phrenic nerve stimulation (PNS)8

and surgical lead revisions9

Improved outcomes

22% relative reduction

in all-cause mortality10

100% of PNS cases

The Quartet LV lead was used to address Phrenic Nerve Stimulation (PNS) cases noninvasively2

Significantly lower capture thresholds

Quartet LV lead has lower capture thresholds when compared to unipolar or bipolar leads3

lower risk of lead deactivation than bipolar leads

Increase in dP/dt with biventricular (BiV) pacing

Increase in dP/dt with biventricular (BiV) pacing

at site of late activation11

Improved hemodynamics12

Reduces Patient and Hospital Costs

Cost analysis performed on a single-center registry showed the Quartet quadripolar LV lead was associated with significantly reduced hospitalizations, specific to heart failure (HF) and left ventricular (LV) lead surgical revision.5

Study Results

  • In-patient heart failure hospitalization rates and LV lead surgical revisions were 54% lower for the quadripolar group (0.15/patient-year than for the bipolar LV group (0.32/patient-year) (p = 0.04).5
  • The hospitalization rate reduction was accompanied with statistically significant cost savings of 62% (p = 0.016).5
Manuals & Resources

Manuals & Resources

Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Forleo, G. B., Mantica, M., Di Biase, L., Panattoni, G., Della Rocca, D. G., Papavasileiou, L. P., … Romeo, F. (2012). Clinical and procedural outcome of patients implanted with a quadripolar left ventricular lead: Early results of a prospective multicenter study. Heart Rhythm, 9(11), 1822-1828. https://dx.doi.org/10.1016/j.hrthm.2012.07.021
  2. Tomassoni, G. Baker, J., Corbisiero, R., Love, C., Martin, D., Niazi, I., … Zhang, Z. (2013). Post-operative performance of the Quartet™ Left Ventriocular Heart Lead. J Cardiovasc Electrophysiol 24(4). 449-456. https://dx.doi.org/10.1111/jce.12065
  3. Turakhia, M. P., Gold, M. R., Fischer, A., Sloman, L. S., Kumar, C., Dalal, N., … Cao, M., (2013). Decreased rate of left ventricular lead deactivation and replacement associated with use of quadripolar LV leads. Europace, 15(Suppl. 2), S47. https://dx.doi.org/10.1093/europace/eut169
  4. Manyam, H., Bhimani, A. A., Sadrpour, S. A., De Oliveira, S. A., Goldstein, R., N., Cakulev, I., … Mackall, J. (2013). Quadripolar left ventricular leads yield lower capture thresholds with expected increase in battery longevity. Heart Rhythm, 10(5) S228. https://doi.org/10.1016/j.hrthm.2013.03.019
  5. Forleo, G. B., Di Biase, L., Bharmi, R., Dalal, N., Panattoni, G., Pollastrelli, A., … Romeo, G. (2015). Hospitalization rates and associated cost analysis of cardiac resynchronization therapy with an implantable defibrillator and quadripolar vs. bipolar left ventricular leads: a comparative effectiveness study. Europace, 17(1), 101-107. https://dx.doi.org/10.1093/europace/euu290
  6. Corbisiero, R., Kazemian, P., Bharmi, R., Shar, R., Muller, D. (2016). Less with More: Hospitalization cost and Event Rates with Quadripolar versus Bipolar CRT-D. PACE 39(10). 1038-1045. https://dx.doi.org/10.1111/pace.12923
  7. Graham, C. M., Gayle, J., & Magee, G. (2014, May). Comparison of healthcare utilization and hospital costs for quadripolar versus bipolar LV lead technologies. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA.
  8. Mehta, P. A., Shetty, A. K., Squirrel, M., Bostock, J., & Rinaldi, C. A. (2012). Elimination of phrenic nerve stimulation occurring during CRT: Follow-up in patients implanted with a novel quadripolar pacing lead. Journal of Interventional Cardiac Electrophysiology, 33(1), 43-49. https://dx.doi.org/10.1007/s10840-011-9598-5
  9. Viani, S. M., Segreti, L., Di Cori, A., Zucchelli, G., Paperinin, L., Soldati, E., … Bongiorni, M. G. (2011). A new quadripolar lead for left ventricular pacing: Short term reliability and future opportunities. Europace, 13(Suppl. 3).
  10. Turakhia, M., Cao, M., Fischer, A., Nabutovsky, Y., Sloman, L. S., Dalal, Nirav., Gold, M. R. (2018). Reduced mortality associated with quadripolar compared to bipolar left ventricular leads in cardiac resynchronization therapy. J Am Coll Cardiol EP. 2(4). 426-33. https://dx.doi.org/10.1016/j.jacep.2016.02.007
  11. Pappone, C., et al. (2012, October). Left ventricular pacing from a site of late electrical activation improves acute hemodynamic response to cardiac resynchronization therapy. Presented at the meeting of the Asia Pacific Heart Rhythm Society, Taipei, Taiwan.
  12. Gutleben, K. J., Kranig, W., Barr, C., Morgenstern, M. M., Simon, M., & Dalal, Y. H. (2011). LV-pacing: Vector optimization using a novel quadripolar electrode acutely improves cardiac output in cardiac resynchronization therapy patients. Europace, 13(3), P403.

MAT-2212654 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0